Publications by authors named "C R Camara-Lemarroy"
Multiple Sclerosis and biological definitions in neurodegenerative diseases.
Mult Scler Relat Disord
December 2024
Recently, biological definitions in Alzheimer´s disease (AD) and Parkinson´s disease (PD) have been proposed, where clinical descriptors such as "dementia" or "parkinsonism" lost the spotlight. Similar changes are in the horizon in Multiple Sclerosis (MS). However, in MS there is no single molecule (like amyloid) to call the main driver of MS pathogenesis.
View Article and Find Full Text PDFElucidating the Significance of Zonulin in the Pathogenesis of Chronic Inflammatory Disorders: Emphasis on Intestinal Barrier Function and Tight Junction Regulation.
Curr Med Chem
September 2024
The intestinal barrier, a critical component of the body's defense system, plays a vital role in maintaining homeostasis by preventing the translocation of harmful substances from the gut lumen into the bloodstream. Disruptions in this barrier, often characterized by increased intestinal permeability, are increasingly recognized as contributors to the development and progression of various Chronic Inflammatory Disorders (CIDs). Zonulin, a key regulator of intestinal Tight Junctions (TJs), has emerged as a pivotal player in this process.
View Article and Find Full Text PDFArticle Synopsis
- While there are many treatment options for relapsing-remitting multiple sclerosis (MS), progressive MS is mostly untreatable, making it a challenge in therapy development.
- Phase 2 clinical trials are crucial for exploring new treatments for progressive MS, but many trials will likely be needed due to the disease's complexity.
- This review highlights strategies like cohort selection, outcome selection, cohort enrichment, and dosing selection to make phase 2 trials more efficient and effective in identifying successful treatments.
Objective: To investigate serum biomarkers of progression in inactive primary progressive multiple sclerosis (PPMS).
Methods: We measured protein biomarkers (growth differentiation factor-15 (GDF-15), dickkopf-1 (DKK-1), neuron specific enolase (NSE) and cathepsin-D) in serum samples from 39 patients with inactive PPMS included in a clinical trial enrolling people with PPMS (clinicaltrials.gov identifier NCT02913157) and investigated the association of these biomarker levels with clinical disability at baseline and during follow-up.